Immunocore Holdings (Nasdaq:IMCR) - Cotización, noticias y análisis

Resumen de acción IMCR

Immunocore Holdings plc, empresa de biotecnología en fase comercial, se dedica al desarrollo de inmunoterapias para el tratamiento del cáncer y las enfermedades infecciosas y autoinmunes.

Acerca de la empresa

IMCR fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	1/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Recompensas

Cotiza un 29.9% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los ingresos de 19.65%

Los analistas coinciden en que el precio de las acciones subirá un 44.6%

Análisis de riesgos

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Los accionistas han sido diluidos en el último año

Competidores de Immunocore Holdings plc

Recursion Pharmaceuticals

NasdaqGS:RXRX

US$1.9b

Global Blood Therapeutics

NasdaqGS:GBT

US$4.6b

Beam Therapeutics

NasdaqGS:BEAM

US$1.7b

ADMA Biologics

NasdaqGM:ADMA

US$1.5b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Immunocore Holdings
Historical stock prices
Current Share Price	US$58.46
52 Week High	US$76.98
52 Week Low	US$42.21
Beta	0.89
1 Month Change	-10.06%
3 Month Change	-18.92%
1 Year Change	0.71%
3 Year Change	44.85%
5 Year Change	n/a
Change since IPO	35.32%

Noticias y actualizaciones recientes

Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?

Apr 05

Recent updates

Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?

Apr 05

Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money

Jan 22

Immunocore Holdings: Vulnerable To Profit Taking After Big Rally

Jan 21

Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%

Dec 18

Some Confidence Is Lacking In Immunocore Holdings plc's (NASDAQ:IMCR) P/S

May 08

Forecast: Analysts Think Immunocore Holdings plc's (NASDAQ:IMCR) Business Prospects Have Improved Drastically

Nov 16

Immunocore: Attractive Commercial-Stage Biopharma

Oct 05

Need To Know: Analysts Are Much More Bullish On Immunocore Holdings plc (NASDAQ:IMCR)

Aug 12

Immunocore GAAP EPS of -$0.17, revenue of $38.92M

Aug 10

Immunocore to raise $140M in private placement financing

Jul 18

Analysts Are Updating Their Immunocore Holdings plc (NASDAQ:IMCR) Estimates After Its Second-Quarter Results

Aug 15

Industry Analysts Just Upgraded Their Immunocore Holdings plc (NASDAQ:IMCR) Revenue Forecasts By 12%

May 20

Rentabilidad de los accionistas

	IMCR	US Biotechs	Mercado US
7D	5.0%	-0.2%	2.9%
1Y	0.7%	-1.0%	22.2%

Rentabilidad vs. Industria: IMCR superó al sector US Biotechs , que obtuvo un rendimiento del -1% el año pasado.

Rentabilidad vs. Mercado: IMCR obtuvo unos resultados inferiores a los del mercado US, que fue del 24.9% el año pasado.

Volatilidad de los precios

Is IMCR's price volatile compared to industry and market?
IMCR volatility
IMCR Average Weekly Movement	5.2%
Biotechs Industry Average Movement	11.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de IMCR ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de IMCR (5%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1999	497	Bahija Jallal	www.immunocore.com

Immunocore Holdings plc, empresa de biotecnología en fase comercial, se dedica al desarrollo de inmunoterapias para el tratamiento del cáncer y las enfermedades infecciosas y autoinmunes. La empresa ofrece KIMMTRAK para el tratamiento de pacientes con melanoma uveal irresecable o metastásico. También desarrolla otros programas para oncología, entre ellos el tebentafusp que se encuentra en ensayo clínico de fase 2/3 para tratar el melanoma cutáneo avanzado.

Resumen de fundamentos de Immunocore Holdings plc

¿Cómo se comparan los beneficios e ingresos de Immunocore Holdings con su capitalización de mercado?
Estadísticas fundamentales de IMCR
Capitalización bursátil	US$2.95b
Beneficios(TTM)	-US$55.29m
Ingresos (TTM)	US$249.43m

11.8x

Ratio precio-ventas (PS)

-53.4x

Ratio precio-beneficio (PE)

¿Está IMCR sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de IMCR
Ingresos	US$249.43m
Coste de los ingresos	US$164.58m
Beneficio bruto	US$84.85m
Otros gastos	US$140.13m
Beneficios	-US$55.29m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-1.10
Margen bruto	34.02%
Margen de beneficio neto	-22.17%
Ratio deuda/patrimonio	13.0%

¿Cómo se ha desempeñado IMCR a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción IMCR

Recompensas

Análisis de riesgos

Competidores de Immunocore Holdings plc

NasdaqGS:RXRX

US$1.9b

NasdaqGS:GBT

US$4.6b

NasdaqGS:BEAM

US$1.7b

NasdaqGM:ADMA

US$1.5b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Insufficient new directors

Immunocore Holdings plc, Annual General Meeting, May 23, 2024

Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?

Board Member notifies of intention to sell stock

Consensus revenue estimates increase by 11%, EPS downgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Insufficient new directors

Immunocore Holdings plc, Annual General Meeting, May 23, 2024

Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?

Board Member notifies of intention to sell stock

Consensus revenue estimates increase by 11%, EPS downgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Immunocore Holdings plc to Report Q4, 2023 Results on Feb 28, 2024

Immunocore Holdings plc Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2023

Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money

Immunocore Holdings: Vulnerable To Profit Taking After Big Rally

Immunocore Holdings plc Announces the Addition of Two New Pre-Clinical Candidates for Autoimmune Diseases to Its Pipeline

CEO & Director notifies of intention to sell stock

Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%

Head of Research & Development notifies of intention to sell stock

Head of Research & Development notifies of intention to sell stock

Consensus EPS estimates upgraded to UK£0.80 loss, revenue downgraded

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Head of Research & Development notifies of intention to sell stock

New major risk - Revenue and earnings growth

Head of Research & Development notifies of intention to sell stock

Head of Research & Development notifies of intention to sell stock

Consensus estimates of losses per share improve by 12%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Immunocore Holdings plc to Report Q2, 2023 Results on Aug 10, 2023

CEO & Director notifies of intention to sell stock

Head of Research & Development notifies of intention to sell stock

Consensus EPS estimates fall by 14%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Some Confidence Is Lacking In Immunocore Holdings plc's (NASDAQ:IMCR) P/S

No longer forecast to breakeven

Consensus EPS estimates fall by 153%, revenue upgraded

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus estimates of losses per share improve by 10%

Immunocore Holdings plc Provides Revenue Guidance for the Fourth Quarter and Twelve Months Ended December 31, 2022

Immunocore Holdings plc Announces the Addition of Three New ImmTAC Product Candidates

Forecast to breakeven in 2025

Consensus forecasts updated

Immunocore Holdings plc Presents Ovarian Cancer Expansion Data for ImmTAC® candidate IMC-C103C targeting MAGE-A4

An unknown buyer acquired a 5% stake in Immunocore Holdings plc (NasdaqGS:IMCR) from Malin Corporation plc (ISE:MLC) for approximately €150 million.

Consensus forecasts updated

Forecast: Analysts Think Immunocore Holdings plc's (NASDAQ:IMCR) Business Prospects Have Improved Drastically

Consensus revenue estimates increase by 27%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

High number of new directors

Immunocore: Attractive Commercial-Stage Biopharma

Consensus revenue estimates increase by 50%

Need To Know: Analysts Are Much More Bullish On Immunocore Holdings plc (NASDAQ:IMCR)

Second quarter 2022 earnings: Revenues exceed analyst expectations

Immunocore GAAP EPS of -$0.17, revenue of $38.92M

Immunocore Holdings plc to Report Q2, 2022 Results on Aug 10, 2022

High number of new directors

Immunocore Holdings plc announced that it has received $139.999988 million in funding from RTW Investments, LP, Rock Springs Capital Management LP, General Atlantic Service Company, L.P., Baker Bros. Advisors LP and another investor

Immunocore Holdings plc announced that it expects to receive $139.999988 million in funding from RTW Investments, LP, Rock Springs Capital Management LP, General Atlantic Service Company, L.P.

Immunocore to raise $140M in private placement financing

Immunocore Announces Dosing of First Patient with ImmTAV(R) Bispecific for HIV

High number of new directors

Immunocore Announces the Presentation of Initial Data from the Phase 1 Immtav® Trial for Chronic Hepatitis B At the EASL International Liver Congress™

Immunocore Holdings plc Appoints Siddharth (Sid) Kaul as A Non-Executive Member of Its Board of Directors